LUNG CANCER

The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data from the eNRGy trial supporting the application.

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.

Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs placebo plus chemotherapy in patients with early-stage non–small cell lung cancer.

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer, according to data from an interim analysis of the phase 3 POLESTAR trial.

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ivonescimab outperforming pembrolizumab in PD-L1-positive advanced non-small cell lung cancer.

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung cancer setting in the second article of a 2-part series.

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in patients with metastatic non–small cell lung cancer.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell lung cancer, based on data from the phase 3 CheckMate 77T trial.

Percy Lee, MD, discussed findings from a trial evaluating a hypofractionated approach to concurrent chemoradiation, incorporating an adaptive stereotactic ablative radiotherapy boost in non–small cell lung cancer.

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.

Xiuning Le, MD, PhD, delved into the background, findings, and next steps of the SOHO-01 study.

The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.

The GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.

Panelists discuss how the latest outcomes from CheckMate-77T demonstrate improved efficacy of neoadjuvant immunotherapy in early-stage non–small cell lung cancer compared with CheckMate-816, potentially revolutionizing treatment strategies and enhancing long-term survival rates for patients with lung cancer.

The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.

In an updated analysis of the phase 3 CheckMate 77T study, perioperative nivolumab showed event-free survival benefits for the treatment of resectable non–small cell lung cancer.

Adagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.

Encorafenib plus binimetinib demonstrated antitumor activity in patients with treatment-naive BRAF V600E-mutant advanced non–small cell lung cancer.

Adding relatlimab to nivolumab and chemotherapy improved clinical benefit in patients with stage IV non–small cell lung cancer compared to nivolumab and chemotherapy alone.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

The novel ROS1 inhibitor zidesamtinib demonstrated promising early activity in heavily pretreated patients with advanced ROS1-fusion-positive non–small cell lung cancer, including in those treated with other next-generation TKIs.

A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not significantly affect overall survival compared to the standard dose.

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated non–small cell lung cancer when compared to dostarlimab alone.

Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.

The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung cancer, regardless of PD-L1 expression.

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer.

Firmonertinib showed efficacy and safety in patients with EGFR PACC-mutated non–small cell lung cancer.